An Interactive Table of Cancer Immunotherapy Options
This table lists immunotherapies that have been approved by the U.S. Food and Drug Administration (FDA) to treat different types of cancer. Some treatments are only used for specific groups of patients based on factors such as cancer type, stage, or biomarkers or genetic testing. The color dots in the table indicate the type of immunotherapy for each treatment.
Afamitresgene autoleucel (Tecelra®)
A modified T cell that targets MAGE-A4 on tumor cells
Lisocabtagene maraleucel (Breyanzi®)
A CD19-targeting CAR T-cell immunotherapy
Aldesleukin (Proleukin®)
A cytokine that targets the IL-2/IL-2R pathway
Mogamulizumab (Poteligeo®)
A monoclonal antibody that targets the CCR4 pathway
Atezolizumab (Tecentriq®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Mosunetuzumab (Lunsumio®)
A bispecific antibody that targets CD20 on lymphoma cells and CD3 on T cells
Avelumab (Bavencio®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Nadofaragene firadenovec (Adstiladrin®)
An adenoviral vector-based gene therapy
Axicabtagene ciloleucel (Yescarta®)
A CD19-targeting CAR T-cell immunotherapy
Nivolumab (Opdivo®)
a checkpoint inhibitor that targets the PD-1/PD-L1 pathway*
Bacillus Calmette-Guérin (BCG) vaccine
Uses weakened bacteria to stimulate the immune system
Nogapendekin alfa inbakicept (Anktiva®)
A cytokine that targets the IL-15 pathway
Blinatumomab (Blincyto®)
A bispecific antibody that targets CD19 on tumor cells and CD3 on T cells
Obecabtagene autoleucel (Aucatzyl®)
A CD19-targeting CAR T-cell immunotherapy
Brexucabtagene autoleucel (Tecartus®)
A CD19-targeting CAR T-cell immunotherapy
Peginterferon alfa-2b (Sylatron™)
A cytokine that targets the interferon pathway
Cemiplimab (Libtayo®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Pembrolizumab (Keytruda®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Ciltacabtagene autoleucel (Carvykti®)
A BCMA-targeting CAR T-cell immunotherapy
Penpulimab (Anniko®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Cosibelimab (Unloxcyt™)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Retifanlimab (Zynyz®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Dostarlimab (Jemperli®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Sipuleucel-T (Provenge®)
A vaccine composed of patient-stimulated dendritic cells
Durvalumab (Imfinzi®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Talimogene laherparepvec (T-VEC) (Imlygic®)
A modified herpes simplex virus (HSV) that infects tumor cells and promotes their destruction
Elranatamab (Elrexfio®)
A bispecific BCMA-directed CD3 T-cell engager
Talquetamab (Talvey®)
A bispecific antibody that targets GPRC5D on tumor cells and CD3 on T cells
Epcoritamab (Epkinly®)
A bispecific antibody that targets CD20 on tumor cells and CD3 on T cells
Tarlatamab (Imdelltra®)
A bispecific antibody that targets DLL3 on cancer cells and CD3 on T cells
Glofitamab (Columvi®)
A bispecific antibody that targets CD20 on tumor cells and CD3 on T cells
Tebentafusp (Kimmtrak®)
A bispecific T-cell engager that targets a gp100 peptide on cells and CD3 on T cells
Idecabtagene vicleucel (Abecma®)
A BCMA-targeting CAR T-cell immunotherapy
Teclistamab (Tecvayli®)
A bispecific antibody that targets BCMA on tumor cells and CD3 on T cells
Imiquimod (Aldara®)
An immune adjuvant targeting the TLR7 pathway
Tisagenlecleucel (Kymriah®)
A CD19-targeting CAR T-cell immunotherapy
Ipilimumab (Yervoy®)
A checkpoint inhibitor that targets the CTLA-4 pathway#
Tislelizumab (Tevimbra®)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Lifileucel (Amtagvi®)
A tumor-derived T-cell immunotherapy
Toripalimab (Loqtorzi™)
A checkpoint inhibitor that targets the PD-1/PD-L1 pathway
Linvoseltamab (Lynozyfic™)
A bispecific BCMA-directed CD3 T-cell engager
Tremelimumab (Imjudo®)
A checkpoint inhibitor that targets the CTLA-4 pathway
No treatments match the selected filters. Please try a different combination.
* Nivolumab + #ipilimumab can be used to treat patients with colorectal cancer and hepatocellular carcinoma (a type of liver cancer).
* Nivolumab + ✝relatlimab (Opdualag®) can be used to treat patients with melanoma.